Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases... Show more
a biotechnology company
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QMMY | 26.51 | 0.15 | +0.58% |
| FT Vest Nasdaq-100 Mod Buffr ETF - May | |||
| PBAU | 31.96 | 0.11 | +0.35% |
| PGIM S&P 500 Buffer 20 ETF - Aug | |||
| FEP | 59.56 | 0.17 | +0.29% |
| First Trust Europe AlphaDEX® ETF | |||
| XOP | 195.72 | 0.25 | +0.13% |
| SttStrtSPDRS&POil&GasExplor&ProdtnETF | |||
| SBB | 23.20 | -0.13 | -0.56% |
| ProShares Short SmallCap600 | |||
A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To DNLI | 1D Price Change % | ||
|---|---|---|---|---|
| DNLI | 100% | -1.45% | ||
| VIR - DNLI | 52% Loosely correlated | +0.38% | ||
| VCYT - DNLI | 50% Loosely correlated | -2.76% | ||
| EDIT - DNLI | 49% Loosely correlated | +1.89% | ||
| BCYC - DNLI | 49% Loosely correlated | +0.78% | ||
| PCVX - DNLI | 48% Loosely correlated | +0.97% | ||
More | ||||
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on August 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for DNLI turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
DNLI moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DNLI crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for DNLI entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.034) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (427.627).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.